Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8053252 | 1.00 | VHL (0.41) | VHLATMCHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL5471213 | 1.00 | VHL (0.41) | VHLATMCHRNB2CHRNA4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2492744 | 0.98 | VHL (0.40) | VHLATMCHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL12051499 | 0.84 | CHRNB2 (0.33) | VHLCHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL15336500 | 0.84 | CHRNB2 (0.33) | VHLCHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL25111569 | 0.84 | CHRNB2 (0.33) | VHLCHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL26207899 | 0.80 | VHL (0.41) | VHLATMCHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL24313223 | 0.79 | ATM (0.41) | ATMCHRNB2CHRNA4ALDH1A1CHRNA7 | |
| SCHEMBL13997593 | 0.79 | ATM (0.34) | VHLATMALDH1A1 | |
| SCHEMBL2501850 | 0.78 | PEPD (0.34) | VHLCHRNB2CHRNA4CHRNA7CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | VHL 171/4885ATM 507/4885CHRNB2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.